Chugai Pharmaceutical Co., Ltd. (CHGCF)
CHGCF Stock Price Chart
Explore Chugai Pharmaceutical Co., Ltd. interactive price chart. Choose custom timeframes to analyze CHGCF price movements and trends.
CHGCF Company Profile
Discover essential business fundamentals and corporate details for Chugai Pharmaceutical Co., Ltd. (CHGCF) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Drug Manufacturers - General
IPO Date
3 Aug 2012
Employees
5.03K
Website
https://www.chugai-pharm.co.jpCEO
Osamu Okuda
Description
Chugai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; osteoporosis, including Actemra, Edirol, and Bonviva; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng. It has various development product candidates in the areas of oncology, immunology, neuroscience, hematology, ophthalmology, and other diseases. Chugai Pharmaceutical Co., Ltd. has strategic alliances with Roche Group; and collaboration and joint research with academia. The company was founded in 1925 and is headquartered in Chuo, Japan. Chugai Pharmaceutical Co., Ltd. is a subsidiary of Roche Holding Ltd.
CHGCF Financial Timeline
Browse a chronological timeline of Chugai Pharmaceutical Co., Ltd. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 22 Apr 2026
Upcoming earnings on 28 Jan 2026
Upcoming earnings on 24 Oct 2025
Revenue estimate is $2.28B.
Earnings released on 24 Jul 2025
EPS came in at $0.40 falling short of the estimated $0.51 by -21.93%, while revenue for the quarter reached $2.01B , missing expectations by -8.52%.
Earnings released on 24 Apr 2025
EPS came in at $0.41 surpassing the estimated $0.34 by +21.66%, while revenue for the quarter reached $1.92B , missing expectations by -14.83%.
Earnings released on 30 Jan 2025
EPS came in at $0.36 surpassing the estimated $0.00 by +14.93K%, while revenue for the quarter reached $1.92B , beating expectations by +17.12%.
Dividend declared on 30 Jan 2025
A dividend of $0.81 per share was announced, adjusted to $0.81. The dividend will be paid on 1 Mar 2026.
Dividend declared on 30 Jan 2025
A dividend of $0.87 per share was announced, adjusted to $0.87. The dividend was paid on 28 Aug 2025.
Dividend declared on 27 Dec 2024
A dividend of $0.36 per share was announced, adjusted to $0.36. The dividend was paid on 28 Mar 2025.
Earnings released on 25 Oct 2024
EPS came in at $0.44 falling short of the estimated $0.45 by -2.90%, while revenue for the quarter reached $2.20B , beating expectations by +6.51%.
Earnings released on 25 Jul 2024
EPS came in at $0.44 surpassing the estimated $0.34 by +30.23%, while revenue for the quarter reached $1.97B , beating expectations by +14.91%.
Earnings released on 24 Apr 2024
EPS came in at $0.29 surpassing the estimated $0.27 by +5.39%, while revenue for the quarter reached $1.56B , missing expectations by -2.60%.
Earnings released on 1 Feb 2024
EPS came in at $0.38 surpassing the estimated $0.33 by +15.24%, while revenue for the quarter reached $1.96B , missing expectations by -3.22%.
Dividend declared on 1 Feb 2024
A dividend of $0.36 per share was announced, adjusted to $0.36. The dividend was paid on 28 Mar 2025.
Dividend declared on 1 Feb 2024
A dividend of $0.25 per share was announced, adjusted to $0.25. The dividend was paid on 29 Aug 2024.
Earnings released on 24 Oct 2023
EPS came in at $0.31 falling short of the estimated $0.35 by -11.19%, while revenue for the quarter reached $1.73B , beating expectations by +10.01%.
Earnings released on 27 Jul 2023
EPS came in at $0.36 surpassing the estimated $0.33 by +10.17%, while revenue for the quarter reached $1.85B , beating expectations by +16.96%.
Earnings released on 27 Apr 2023
EPS came in at $0.33 falling short of the estimated $0.33 by -0.27%, while revenue for the quarter reached $2.36B , beating expectations by +10.41%.
Earnings released on 2 Feb 2023
EPS came in at $0.48 surpassing the estimated $0.45 by +6.75%, while revenue for the quarter reached $3.38B , beating expectations by +12.89%.
Dividend declared on 2 Feb 2023
A dividend of $0.28 per share was announced, adjusted to $0.28. The dividend was paid on 29 Mar 2024.
Dividend declared on 2 Feb 2023
A dividend of $0.28 per share was announced, adjusted to $0.28. The dividend was paid on 30 Aug 2023.
Earnings released on 24 Oct 2022
EPS came in at $0.28 falling short of the estimated $0.31 by -8.44%, while revenue for the quarter reached $1.56B , missing expectations by -17.28%.
Earnings released on 21 Jul 2022
EPS came in at $0.32 matching the estimated $0.32, while revenue for the quarter reached $1.73B , missing expectations by -5.59%.
Earnings released on 25 Apr 2022
EPS came in at $0.62 surpassing the estimated $0.28 by +122.46%, while revenue for the quarter reached $2.95B , beating expectations by +17.82%.
Earnings released on 3 Feb 2022
EPS came in at $0.52 surpassing the estimated $0.47 by +10.15%, while revenue for the quarter reached $2.80B , beating expectations by +7.94%.
Dividend declared on 3 Feb 2022
A dividend of $0.30 per share was announced, adjusted to $0.28. The dividend was paid on 31 Mar 2023.
Dividend declared on 3 Feb 2022
A dividend of $0.28 per share was announced, adjusted to $0.28. The dividend was paid on 30 Aug 2022.
Earnings released on 22 Oct 2021
EPS came in at $0.46 surpassing the estimated $0.34 by +35.56%, while revenue for the quarter reached $2.58B , beating expectations by +1.06K%.
Earnings released on 26 Jul 2021
EPS came in at $0.39 , while revenue for the quarter reached $1.99B .
Earnings released on 22 Apr 2021
EPS came in at $0.27 falling short of the estimated $0.32 by -15.67%, while revenue for the quarter reached $1.53B .
Earnings released on 4 Feb 2021
EPS came in at $0.30 , while revenue for the quarter reached $2.04B .
Dividend declared on 4 Feb 2021
A dividend of $0.40 per share was announced, adjusted to $0.40. The dividend was paid on 30 Mar 2022.
Dividend declared on 4 Feb 2021
A dividend of $0.27 per share was announced, adjusted to $0.27. The dividend was paid on 30 Aug 2021.
Earnings released on 22 Oct 2020
EPS came in at $0.35 surpassing the estimated $0.30 by +18.00%, while revenue for the quarter reached $1.97B .
Dividend declared on 30 Jan 2020
A dividend of $0.29 per share was announced, adjusted to $0.24. The dividend was paid on 24 Mar 2021.
CHGCF Stock Performance
Access detailed CHGCF performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.